Medtronic has received the CE Mark for its SenSight direction lead system for deep brain stimulation (DBS) therapy.
The therapy has been developed to treat symptoms related to movement disorders and epilepsy. It uses a small device similar to a pacemaker to send electrical signals through thin wires, which target areas in the brain related to these symptoms.
The SenSight system has been developed with the help of collaboration with clinicians, which means it is able to work seamlessly alongside Medtronic neurostimulators including the Percept PC neurostimulator.
According to Medtronic, the system will boost the identification of local field potentials (LFPs) and provide patients with direction stimulation that offers a customised data to enable them to access tailored treatment.
SenSight directional lead systems were first used by multi-disciplinary teams on 17th and 18th March at University Clinic of Würzburg and Grenoble Alpes University Hospital, with a full launch set to follow this latest announcement.
Commenting on the news, Medtronic brain modulation vice-president and general manager Mike Daly said: "Medtronic has been driving innovation in DBS therapy for more than 25 years and the approval of the SenSight directional lead system in the EU is our latest contribution to the quest for improved patient experiences and clinical outcomes."